Lantheus Holdings
LNTH • NASDAQ
Lantheus Holdings is a drug manufacturers - specialty & generic company in the healthcare sector trading on NASDAQ, led by CEO Mary Anne Heino, with a market cap of $4.8B.
CEOMary Anne Heino
Next Earnings
Upcoming earnings announcement for Lantheus Holdings
Date
Wednesday, May 6, 2026 (in a month)
Timing
Before Market Open (7:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$1.15
Revenue Estimate
$357.0M
Earnings History
Past 12 earnings reports for Lantheus Holdings
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Q4 2025 | $1.67Est: $1.08 | +54.6% | $406.8MEst: $367.3M | +10.7% |  10-K |
| Nov 6, 2025 | Q3 2025 | $1.27Est: $1.18 | +7.6% | $384.0MEst: $364.4M | +5.4% | 10-Q |
| Aug 6, 2025 | Q2 2025 | $1.57Est: $1.58 | -0.6% | $378.0MEst: $388.3M | -2.6% | 10-Q |
| May 7, 2025 | Q1 2025 | $1.53Est: $1.63 | -6.1% | $372.6MEst: $377.2M | -1.2% | 10-Q |
| Feb 26, 2025 | Q4 2024 | $1.59Est: $1.54 | +3.2% | $391.1MEst: $376.2M | +4.0% | 10-K |
| Nov 6, 2024 | Q3 2024 | $1.70Est: $1.56 | +9.0% | $378.7MEst: $371.7M | +1.9% | 10-Q |
| Jul 31, 2024 | Q2 2024 | $1.80Est: $1.83 | -1.6% | $394.1MEst: $382.0M | +3.2% | 10-Q |
| May 2, 2024 | Q1 2024 | $1.69Est: $1.54 | +9.7% | $370.0MEst: $348.5M | +6.2% | 10-Q |
| Feb 22, 2024 | Q4 2023 | $1.75Est: $1.45 | +20.7% | $354.0MEst: $342.3M | +3.4% | 10-K |
| Nov 2, 2023 | Q3 2023 | $1.47Est: $1.32 | +11.4% | $319.9MEst: $314.3M | +1.8% | — |
| Aug 3, 2023 | Q2 2023 | $1.54Est: $1.33 | +15.8% | $321.7MEst: $306.5M | +5.0% | 10-Q |
| May 4, 2023 | Q1 2023 | $1.47Est: $1.26 | +16.7% | $300.8MEst: $280.6M | +7.2% | — |